1001-1 Interleukin-6 is a better predictor of mortality than C-reactive protein very early after symptom onset in patients with non-ST elevation acute coronary syndrome  by James, Stefan et al.
JACC March 3, 2004 ABSTRACTS - Featured Poster  1A
Featured Poster
FEATURED POSTER
1001 
Sunday Featured Poster Presentations
Sunday, March 07, 2004, 9:00 a.m.-5:00 p.m.
Morial Convention Center, Hall G
Presentation Hour: Noon-1:00 p.m.
Noon
1001-1 Interleukin-6 Is a Better Predictor of Mortality Than C-
Reactive Protein Very Early After Symptom Onset in 
Patients With Non-ST Elevation Acute Coronary 
Syndrome
Stefan James, Agneta Siegbahn, Lars Wallentin, Inst. of Medical Sciences, Uppsala, 
Sweden
Background: Markers of inflammatory activity are predictors of mortality in patients with
non-ST elevation acute coronary syndromes (ACS). Interleukin-6 (Il-6) is the initiator of
C-reactive protein (CRP) release from the liver and therefore an earlier inflammatory
marker.
Methods: The GUSTO-IV trial enrolled 7800 patients with non-ST elevation at a median
of 9.5 hours after symptom onset. We analyzed baseline levels of Il-6 in 6857 patients
and CRP in 7108 patients. One-year mortality was compared between patients with and
without elevation ( 10ng/L for Il-6 and 10mg/L for CRP) of the markers enrolled at differ-
ent time-intervals after symptom onset.
Conclusion: In non-ST elevation ACS, elevation of Il-6 seems to provide the best predic-
tion of high and low long-term mortality in patients admitted within 6 hours after symptom
onset. Thereafter, elevation of Il-6 and CRP seem to provide a similar mortality predic-
tion.
Results:
 
Noon
1001-2 Is the “Hub-and-Spoke” Model Working? Patterns of 
Transfer for High-Risk Acute Coronary Syndromes 
Patients From Community Hospitals Without 
Revascularization Capacity
Matthew T. Roe, William E. Boden, Anita Chen, James E. Calvin, Jr., Sidney C. Smith, 
Jr., E. Magnus Ohman, W. Brian Gibler, Charles V. Pollack, Jr., Ralph G. Brindis, Robert 
M. Califf, Eric D. Peterson, Duke Clinical Research Institute, Duke University Medical 
Center, Durham, NC, Hartford Hospital, Hartford, CT
Background: Current ACC/AHA Guidelines for treating non–ST-segment elevation acute
coronary syndromes (NSTE ACS) recommend early invasive management for high-risk
patients. Yet transfer patterns for high-risk patients who present to community hospitals
without revascularization capabilities are not well-characterized.
Methods: Using data from the CRUSADE Initiative, we compared the clinical character-
istics of 9,712 NSTE ACS patients (positive cardiac markers and/or ischemic ST-segment
changes) who were transferred early (within 48 h), late (after 48 h), or not at all from 106
community hospitals (45 without cath labs, 61 with cath labs only) in the U.S.
Results: Only 18.7% of high-risk NSTE ACS patients were transferred from nonrevascu-
larization hospitals within 48 h; another 27.2% were transferred late. Age, socioeconomic
characteristics, and patient risk factors all correlated with transfer selection (Table). Low-
risk patients were transferred early, but frequently the highest-risk patients were never
transferred.
Conclusions: Community hospitals without revascularization capabilities currently fail to
transfer a large percentage of high-risk NSTE ACS patients. Patients with the highest
risk, who stand to benefit the most, are paradoxically least likely to be transferred. These
findings support enhancing NSTE ACS patient triage using a “hub-and-spoke” system of
regionalized tertiary referral for high-risk patients. 
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1001-3 Urinary Tract Infection in Patients With Acute Coronary 
Syndrome: A Potential Systemic Inflammatory 
Connection
John B. Sims, James A. de Lemos, Param Maewal, Velma Yettman, John J. Warner, 
Darren K. McGuire, UT Southwestern, Dallas, TX
Background: Inflammation has been linked with atherosclerotic disease development
and instability. Contributors to systemic inflammation, such as subclinical infection, may
precipitate acute coronary syndromes (ACS).
Methods: Using a retrospective chart review, case-control study, we evaluated the preva-
lence of urinary tract infection (UTI), defined as WBC>5 per high-power field on urinalysis
(UA) collected <6 hours after arrival, among consecutive ACS patients at a university
hospital, compared with a contemporary control cohort of patients undergoing elective
coronary artery bypass graft (CABG) surgery. Patients were excluded from the case
cohort if ACS (non ST-elevation myocardial infarction (MI) or unstable angina) was not
confirmed by chart review; or if a UA was not obtained within 6 hours of arrival. Patients
excluded from the control cohort were those with MI <21 days prior to CABG or without a
pre-CABG UA.
Results: We analyzed data from 100 consecutive patients with ACS and 100 contempo-
rary elective CABG patients. The cohorts were well matched with regard to clinical char-
acteristics, with the only significant differences being more congestive heart failure
(OR=7.26, 95% CI 3.31-15.93) and less prior MI (OR=0.48, 95% CI 0.25-0.90) in the
CABG cohort. UTI was present in 27 of the ACS and 11 of the control patients. Among
ACS patients, those with UTI tended to be older, more often female and diabetic, more
often had a history of hyperlipidemia, hypertension, and renal insufficiency, and more
commonly presented with non-ST elevation MI. In unadjusted analysis, UTI was almost
three times more common in the case group compared with the control group (OR=2.99,
95% CI 1.39-6.44). This difference remained statistically significant after multivariable
adjustment for differences in patient characteristics (OR=2.99, 95% CI, 1.31-6.82).
Conclusion: Sub-clinical UTI is common among patients with ACS. Underlying infection
may be a precipitator of ACS via activation of systemic inflammation. This hypothesis
should be explored in other datasets, and similar relationships with other bacterial and
viral infections should be examined.
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1001-4 Impact of Initial Patency of the Infarct Related Vessel on 
Outcome in Patients With Acute Myocardial Infarction 
Treated With Primary Angioplasty
Nicolette Ernst, Felix Zijlstra, Menko-Jan de Boer, Harry Suryapranata, Jan C. Hoorntje, 
Kor Miedema, Jan-Henk E. Dambrink, Marcel Gosselink, Arnoud W. van 't Hof, Isala 
Klinieken, locatie Weezenlanden, Zwolle, The Netherlands
Background: Patients (pts) with acute myocardial infarction (MI), treated with primary
angioplasty (PA) in whom TIMI 3 flow of the infarct related vessel (IRV) is seen at acute
angiography, have a better clinical outcome compared to pts without TIMI 3 flow as initial
patency. Little is known about the relationship between any increase in initial TIMI flow
and outcome.
Methods: We studied angiographic and clinical data of 1702 consecutive pts with acute
MI treated with PA. Initial TIMI flow of the IRV and myocardial blush grade (MBG) were
assessed by core lab analysis. Enzymatic infarct size was determined by serial measure-
ments of lactate dehydrogenase up to 48 hours after onset of symptoms (LDHQ48). At
Transfer rates by patient characteristics and risk factors
No Catheterization Lab
(n=3,689)
Catheterization Lab Only
(n=6,023)
Transferre
d Within 
48 h
(n=804)
Transferre
d After 48 
h
(n=1,105)
Not 
Transfe
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(n=1,7
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d Within 
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h
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Characteristic
Median age,* yrs 
(25th, 75th 
percentile)
63 (53,74) 69 (59,77) 77 
(66,85)
62 (52,72) 69 (57,78) 74 
(61,83)
Female sex,* % 34.3 37.6 48.2 32.1 36.4 47.3
African-American,* 
%
6.1 9.0 11.0 7.9 8.2 19.4
Medicaid/
Medicare,* %
40.9 52.4 66.7 39.3 49.6 59.6
CHF at 
presentation,* %
14.4 23.5 33.0 13.9 25.9 33.0
Renal 
insufficiency,* %
4.5 10.7 17.1 6.7 9.0 21.1
*p<0.0001 among transfer groups
